Checkmate Pharmaceuticals

Overview

• Industrypharmaceutical industry¹
• HeadquartersCambridge¹
• Websitecheckmatepharma.com
• Incorporated inDE³
• Business address245 Main Street, 2Nd Floor, Cambridge, Ma 02142³
• Filer category, Emerging growth company³

See how the biggest companies compare on our leaderboards

Corporate structure

Checkmate Pharmaceuticals sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Checkmate Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Leadership

Who has led Checkmate Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerAlan Bash Mar 2, 2022 to May 31, 2022⁸
• Chief executive officerBarry Labinger Aug 6, 2020 to Aug 6, 2021⁹
• PresidentBarry Labinger Aug 6, 2020 to Aug 6, 2021⁹
• Chief financial officerRobert Dolski Jan 14, 2021 to May 31, 2022¹⁰
• Chief operating officerKaren Brennan Aug 6, 2020 to Aug 10, 2020¹¹

Timeline

1. May 31, 20228-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights²⁴
2. May 12, 20228-K Results of operations²⁵
3. Apr 19, 20228-K Other events²⁶
4. Apr 19, 20228-K Entered a material agreement²⁷
5. Mar 30, 20228-K Results of operations²⁸
6. Mar 2, 2022New chief executive Alan Bash becomes CEO⁸
7. Mar 1, 20228-K Executive or director change²⁹
8. Feb 9, 20228-K Executive or director change³⁰
9. Feb 1, 20228-K Executive or director change³¹
10. Dec 21, 20218-K Executive or director change³²
11. Dec 14, 20218-K Regulation FD disclosure; Other events³³
12. Nov 12, 20218-K Results of operations³⁴
13. Oct 27, 20218-K Executive or director change; Regulation FD disclosure³⁵
14. Aug 6, 2020New chief executive Barry Labinger becomes CEO⁹
15. 2015Founded Founded¹

Calendar

When it reported results

1. May 12, 2022Reported quarterly or annual results²⁵
2. Mar 30, 2022Reported quarterly or annual results²⁸
3. Nov 12, 2021Reported quarterly or annual results³⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

68 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 13 major events, 28 insider forms, 9 large holders, 14 other. The latest 20:

1. Jun 10, 202215-12B EDGAR
2. Jun 7, 2022SC 13G/A EDGAR
3. Jun 7, 2022SC 13D/A SCHEDULE 13D - AMENDMENT NO. 1 EDGAR
4. Jun 3, 2022SC 13D/A EDGAR
5. Jun 3, 2022SC 13D SCHEDULE 13D - CHECKMATE PHARMACEUTICALS, INC. EDGAR
6. Jun 1, 2022EFFECT EDGAR
7. May 31, 2022SC 14D9/A EDGAR
8. May 31, 2022S-8 POS EDGAR
9. May 31, 2022S-8 POS EDGAR
10. May 31, 2022S-8 POS EDGAR
11. May 31, 2022POS AM EDGAR
12. May 31, 20228-K EDGAR
13. May 31, 20224 FORM 4 SUBMISSION EDGAR
14. May 31, 20224 FORM 4 SUBMISSION EDGAR
15. May 31, 20224 FORM 4 SUBMISSION EDGAR
16. May 31, 20224 FORM 4 SUBMISSION EDGAR
17. May 31, 20224 FORM 4 SUBMISSION EDGAR
18. May 31, 20224 FORM 4 SUBMISSION EDGAR
19. May 31, 20224 FORM 4 SUBMISSION EDGAR
20. May 31, 20224 FORM 4 SUBMISSION EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 0 buys and 23 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• GARDNER LEWIS ASSET MANAGEMENT L PSC 13D/A, 2 filings Jun 3, 2022 to Jun 7, 2022³⁶
• venBio Global Strategic Fund II L.P.SC 13G/A, 2 filings May 5, 2022 to Jun 7, 2022³⁷
• Novo Holdings A/SSC 13D/A, 3 filings Nov 1, 2021 to Jun 3, 2022³⁸
• CLOUGH CAPITAL PARTNERS L PSC 13G/A, 1 filing Feb 14, 2022³⁹
• Decheng Capital Management III (Cayman), LLCSC 13G, 1 filing Feb 14, 2022⁴⁰

SEC filer profile

How Checkmate Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCheckmate Pharmaceuticals, Inc.²
• CIK0001651431
• Employer ID (EIN)36-4813934²
• Filer status<br>emerging growth company²
• Incorporated inDelaware²
• Fiscal year endsDecember 31²
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)²
• Business address245 Main Street, 2Nd Floor, Cambridge, MA 02142²
• Phone978-503-2124²
• Shares outstanding22,038,218 as of May 12, 2022⁶
• Public float$124.0M as of Jun 30, 2021⁷
• On EDGAR sinceAug 25, 2015²
• Filings187 in all: 4 (59), 8-K (26), 3 (18), 10-Q (6), CORRESP (6), D (6), SC 13G (5), SC 13G/A (5)²
  All 38 form types

  D/A (4), SC 13D (4), SC 13D/A (4), UPLOAD (4), EFFECT (3), S-8 (3), S-8 POS (3), SC 14D9/A (3), SC TO-T/A (3), SC14D9C (3), 10-K (2), DRS/A (2), 10-K/A (1), 15-12B (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DEFA14A (1), DRS (1), DRSLTR (1), POS AM (1), S-1 (1), S-1/A (1), S-3 (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1)

• Latest filingsAnnual report (10-K) Mar 30, 2022
  Quarterly report (10-Q) May 12, 2022
  Proxy statement (DEF 14A) Apr 27, 2021
  Latest 8-K (8-K) May 31, 2022

Links

• Websitecheckmatepharma.com¹
• WikidataQ113503545
• SEC EDGARCIK 1651431